Switch theme
Sign up to access all valuation multiples
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.
1984
3
LTM Revenue $7.2M
LTM EBITDA -$34.3M
$436M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Botanix Pharmaceuticals has a last 12-month revenue (LTM) of $7.2M and a last 12-month EBITDA of -$34.3M.
In the most recent fiscal year, Botanix Pharmaceuticals achieved revenue of $0.4M and an EBITDA of -$8.9M.
Botanix Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Botanix Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.2M | XXX | $0.4M | XXX | XXX | XXX |
| Gross Profit | $4.7M | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | -$34.3M | XXX | -$8.9M | XXX | XXX | XXX |
| EBITDA Margin | -476% | XXX | -2291% | XXX | XXX | XXX |
| EBIT | -$35.7M | XXX | -$9.9M | XXX | XXX | XXX |
| EBIT Margin | -497% | XXX | -2569% | XXX | XXX | XXX |
| Net Profit | -$35.3M | XXX | -$8.9M | XXX | XXX | XXX |
| Net Margin | -490% | XXX | -2305% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Botanix Pharmaceuticals's stock price is AUD 0 (or $0).
Botanix Pharmaceuticals has current market cap of AUD 726M (or $466M), and EV of AUD 678M (or $436M).
See Botanix Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $436M | $466M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Botanix Pharmaceuticals has market cap of $466M and EV of $436M.
Botanix Pharmaceuticals's trades at 106.3x EV/Revenue multiple, and -19.2x EV/EBITDA.
Equity research analysts estimate Botanix Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Botanix Pharmaceuticals has a P/E ratio of -13.2x.
See valuation multiples for Botanix Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $466M | XXX | $466M | XXX | XXX | XXX |
| EV (current) | $436M | XXX | $436M | XXX | XXX | XXX |
| EV/Revenue | 60.5x | XXX | 106.3x | XXX | XXX | XXX |
| EV/EBITDA | -12.7x | XXX | -19.2x | XXX | XXX | XXX |
| EV/EBIT | -12.2x | XXX | -18.1x | XXX | XXX | XXX |
| EV/Gross Profit | 93.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.2x | XXX | -20.0x | XXX | XXX | XXX |
| EV/FCF | -11.0x | XXX | -14.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBotanix Pharmaceuticals's last 12 month revenue growth is 837%
Botanix Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $3.4M for the same period.
Botanix Pharmaceuticals's rule of 40 is -2391% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Botanix Pharmaceuticals's rule of X is 1617% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Botanix Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 837% | XXX | 408% | XXX | XXX | XXX |
| EBITDA Margin | -476% | XXX | -554% | XXX | XXX | XXX |
| EBITDA Growth | -104% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2391% | XXX | 283% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 1617% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 301% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2669% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Botanix Pharmaceuticals acquired XXX companies to date.
Last acquisition by Botanix Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Botanix Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Botanix Pharmaceuticals founded? | Botanix Pharmaceuticals was founded in 1984. |
| Where is Botanix Pharmaceuticals headquartered? | Botanix Pharmaceuticals is headquartered in Australia. |
| How many employees does Botanix Pharmaceuticals have? | As of today, Botanix Pharmaceuticals has 3 employees. |
| Is Botanix Pharmaceuticals publicy listed? | Yes, Botanix Pharmaceuticals is a public company listed on ASX. |
| What is the stock symbol of Botanix Pharmaceuticals? | Botanix Pharmaceuticals trades under BOT ticker. |
| When did Botanix Pharmaceuticals go public? | Botanix Pharmaceuticals went public in 1985. |
| Who are competitors of Botanix Pharmaceuticals? | Similar companies to Botanix Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Botanix Pharmaceuticals? | Botanix Pharmaceuticals's current market cap is $466M |
| What is the current revenue of Botanix Pharmaceuticals? | Botanix Pharmaceuticals's last 12 months revenue is $7.2M. |
| What is the current revenue growth of Botanix Pharmaceuticals? | Botanix Pharmaceuticals revenue growth (NTM/LTM) is 837%. |
| What is the current EV/Revenue multiple of Botanix Pharmaceuticals? | Current revenue multiple of Botanix Pharmaceuticals is 60.5x. |
| Is Botanix Pharmaceuticals profitable? | Yes, Botanix Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Botanix Pharmaceuticals? | Botanix Pharmaceuticals's last 12 months EBITDA is -$34.3M. |
| What is Botanix Pharmaceuticals's EBITDA margin? | Botanix Pharmaceuticals's last 12 months EBITDA margin is -476%. |
| What is the current EV/EBITDA multiple of Botanix Pharmaceuticals? | Current EBITDA multiple of Botanix Pharmaceuticals is -12.7x. |
| What is the current FCF of Botanix Pharmaceuticals? | Botanix Pharmaceuticals's last 12 months FCF is -$39.5M. |
| What is Botanix Pharmaceuticals's FCF margin? | Botanix Pharmaceuticals's last 12 months FCF margin is -548%. |
| What is the current EV/FCF multiple of Botanix Pharmaceuticals? | Current FCF multiple of Botanix Pharmaceuticals is -11.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
